根据协议条款,若在特定情况下合并交易终止,Ventyx Biosciences, Inc.将需向礼来公司支付高达4400万美元的终止费用。这一条款明确了双方在并购过程中的财务责任边界,凸显了交易执行的风险管控机制。
根据协议条款,若在特定情况下合并交易终止,Ventyx Biosciences, Inc.将需向礼来公司支付高达4400万美元的终止费用。这一条款明确了双方在并购过程中的财务责任边界,凸显了交易执行的风险管控机制。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.